Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database

被引:58
|
作者
Iarikov D. [1 ]
Wassel R. [1 ]
Farley J. [1 ]
Nambiar S. [1 ]
机构
[1] US Food and Drug Administration, Silver Spring, MD
关键词
Fosfomycin; Fosfomycin adverse events; Fosfomycin safety;
D O I
10.1007/s40121-015-0092-8
中图分类号
学科分类号
摘要
Introduction: The growing problem of antibacterial resistance resulted in an increased interest in fosfomycin, especially its parenteral formulation. We reviewed fosfomycin safety profile using the Food and Drug Administration Adverse Event (AE) Reporting System (FAERS) and published literature. Methods: We conducted a FAERS search and disproportionality analysis of all fosfomycin-associated AEs. We also conducted a FAERS search for AEs implicating fosfomycin as the primary suspect and a search of reports of fosfomycin-associated bone marrow toxicity. We then review the literature for publications reporting AEs associated with fosfomycin by conducting PubMed searches. Results: The disproportionality analysis of all FAERS reports of fosfomycin-associated AEs produced a higher than expected frequency of agranulocytosis, liver injury, severe skin reactions, and pseudomembranous colitis. Subsequent search for AEs where fosfomycin was the primary suspect and the literature review did not suggest a higher association of fosfomycin with these AEs. The search of bone marrow toxicity reports did not demonstrate an association between aplastic anemia and fosfomycin. The literature review selected 23 trials of parenteral administration of fosfomycin in 1242 patients including 8 comparative and 15 non-comparative trials. For oral fosfomycin, only prospective comparative trials (n = 28) in 2743 patients were included. The most frequent AEs associated with parenteral fosfomycin included rash, peripheral phlebitis, hypokalemia, and gastrointestinal disorders. Serious AEs such as aplastic anemia, anaphylaxis, and liver toxicities were reported infrequently. Gastrointestinal disorders were the most common AEs associated with oral fosfomycin. Conclusion: The identified AEs were consistent with the safety profile of fosfomycin. No new safety signals related to either parenteral or oral fosfomycin were identified. © 2015, The Author(s).
引用
收藏
页码:433 / 458
页数:25
相关论文
共 50 条
  • [1] Adverse Events Associated with Belimumab Use in Pediatric Patients: Review and Analyses of the FDA Adverse Event Reporting System Database
    Kim, Ivone
    Ryan, Debra
    Cheng, Carmen
    Kortepeter, Cindy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2683 - 2684
  • [2] Fosfomycin-associated adverse events: A disproportionality analysis of the FDA Adverse Event Reporting System
    Yang, Luxuan
    Zhang, Wenyong
    Shen, Xiujuan
    Liu, Meiqin
    Wu, Meiying
    Xiao, Dan
    DRUG DISCOVERIES AND THERAPEUTICS, 2025,
  • [3] Assessing taxane-associated adverse events using the FDA adverse event reporting system database
    Lao, Dong-Hui
    Chen, Ye
    Fan, Jun
    Zhang, Jian-Zhong
    CHINESE MEDICAL JOURNAL, 2021, 134 (12) : 1471 - 1476
  • [4] A Review of Dental Adverse Events Using the FDA Adverse Event Reporting System
    Altman, Keith
    Budny, Renata
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 400 - 400
  • [5] Novel adverse events of blonanserin: a disproportionality analysis in the FDA Adverse Event Reporting System database
    Subeesh, Viswam
    Singh, Hemendra
    Maheswari, Eswaran
    Beulah, Thomas
    MINERVA PSICHIATRICA, 2018, 59 (02): : 105 - 110
  • [6] EXPLORING THE INCREASED SERIOUS ADVERSE EVENTS ASSOCIATED WITH INHALED TREPROSTINIL: AN FDA ADVERSE EVENT REPORTING SYSTEM DATABASE ANALYSIS
    Oli, Sharad
    Oli, Shital
    Niraula, Sristee
    Khanal, Resha
    CHEST, 2024, 166 (04) : 3535A - 3535A
  • [7] DRUGS ASSOCIATED WITH ADVERSE DRUG EVENTS IN CHILDREN: ANALYSIS OF THE UNITED STATES FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Lee, W. J.
    Schumock, G. T.
    Lee, T. A.
    VALUE IN HEALTH, 2013, 16 (03) : A70 - A70
  • [8] Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
    Lin, Shan
    Luo, Dachen
    Gong, Zonglian
    Zhan, Qingyuan
    FRONTIERS IN MEDICINE, 2024, 11
  • [9] Metoprolol adverse events and literature analyses: case/non-case analyses using the FDA Adverse Event Reporting System (FAERS)
    Du, Yikuan
    Zhang, Mengting
    Luo, Ziyi
    Liang, Zhonghan
    Liang, Weijian
    Chen, Zhixing
    Fan, Ruiyun
    Huang, Yin
    Li, Jiaqi
    Hu, Mianda
    Li, Jiahui
    Zhu, Jinfeng
    Zhang, Weichui
    Liu, Yi
    Yang, Chun
    EXPERT OPINION ON DRUG SAFETY, 2024,
  • [10] Ocular Adverse Events Associated with Biologics Approved for Psoriasis: An FDA Adverse Event Reporting Database Study
    Katsiaunis, Apostolos
    Lipner, Shari R.
    JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2025, 29 (01) : 99 - 100